Log In
BCIQ
Print this Print this
 

SIRPalphaFc (TTI-621)

  Manage Alerts
Collapse Summary General Information
Company Trillium Therapeutics Inc.
DescriptionFusion protein comprising the CD47-binding domain of signal regulatory protein alpha (SIRPA) and the Fc domain of IgG, which acts as a soluble decoy receptor to block CD47
Molecular Target CD47
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2.9M

$1.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/02/2014

$2.9M

$1.2M

0

Get a free BioCentury trial today